Biotech News
Related news
LYELLyell Immunopharma2026-06-25 12:00 EST
Lyell Immunopharma Announces Participation in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
CMPXCompass Therapeutics2026-07-17 14:42 EST
Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026
RVMDRevolution Medicines2026-06-24 23:31 EST
Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
ZNTLZentalis2026-07-17 20:15 EST
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
NKTXNkarta2026-08-10 20:24 EST
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
COGTCogent Biosciences2026-06-12 12:01 EST
Cogent Biosciences Announces Preclinical Data from Novel JAK2 V617F Inhibitor at the 2026 European Hematology Association (EHA) Congress
KURAKura Oncology2026-07-14 11:02 EST
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
MMSIMerit Medical2026-08-05 16:00 EST
Merit Medical to Participate in Upcoming Investors Conferences in August
GSKGSK plc2026-07-29 09:08 EST
Cabenuva demonstrates superiority to daily oral therapy in adolescents living with HIV, as ViiV Healthcare highlights new long-acting injectable data at AIDS 2026
GSKGSK plc2026-07-27 14:55 EST
ViiV Healthcare’s 2-drug regimen Dovato is as effective as 3-drug regimen Biktarvy in first-of-its-kind head-to-head study in treatment-naïve adults living with HIV
Nkarta
Allogeneic CAR-NK Company Nkarta develops off-the-shelf natural killer cell therapies for autoimmune disease and cancer. NKX019 NKX019 is a CD19-directed CAR-NK therapy designed to deplete pathogenic B cells without patient-specific manufacturing. Ntrust Studies Ntrust-1 and Ntrust-2 evaluate NKX019 across autoimmune diseases with...
Recent company news
NKTXNkarta2026-08-10 20:24 EST
Nkarta Reports Second Quarter 2026 Financial Results and Corporate Highlights
NKTXNkarta2026-05-12 20:01 EST
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
NKTXNkarta2026-04-15 20:01 EST
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
NKTXNkarta2026-04-09 11:00 EST
Nkarta to Participate in Needham Virtual Healthcare Conference
NKTXNkarta2026-03-25 20:01 EST
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
Stock data
- Close
- 2.43 USD
- Market cap
- 208.2M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States